"Mechanism Of Action Of Selinexor In Myeloma" - Sundar Jagannath, MD

Sundar Jagannath, MD, professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types. Selinexor is an orally available selective inhibitor of a nuclear export that blocks the nuclear export protein CRM1, which is responsible for exporting all the tumor inhibitory molecules. These cells will then go into arrest or death, Dr. Jagannath said. There is excitement with this agent because it has shown impact in multiple myeloma, acute myeloid leukemia, and even solid tumors.

- Sundar Jagannath, MD, Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai

Learn more